Jeff Martin
Stock Analyst at Roth Capital
(3.54)
# 873
Out of 5,030 analysts
62
Total ratings
60.34%
Success rate
17.76%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSP Insperity | Maintains: Buy | $85 → $74 | $47.32 | +56.38% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $17.55 | +53.85% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $4.78 | +4.60% | 1 | May 14, 2025 | |
| PERI Perion Network | Upgrades: Buy | $9 → $14 | $9.56 | +46.44% | 9 | May 14, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $224 → $245 | $246.74 | -0.71% | 16 | May 2, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $3.79 | +137.47% | 1 | Mar 20, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $42.15 | +6.76% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $18.88 | +58.90% | 6 | Nov 5, 2024 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $47 → $43 | $43.47 | -1.08% | 5 | Aug 8, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $1.41 | +408,410.64% | 2 | Nov 15, 2017 |
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $47.32
Upside: +56.38%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $17.55
Upside: +53.85%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $4.78
Upside: +4.60%
Perion Network
May 14, 2025
Upgrades: Buy
Price Target: $9 → $14
Current: $9.56
Upside: +46.44%
OSI Systems
May 2, 2025
Maintains: Buy
Price Target: $224 → $245
Current: $246.74
Upside: -0.71%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.79
Upside: +137.47%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $42.15
Upside: +6.76%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $18.88
Upside: +58.90%
Bowman Consulting Group
Aug 8, 2024
Maintains: Buy
Price Target: $47 → $43
Current: $43.47
Upside: -1.08%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $1.41
Upside: +408,410.64%